Original ArticleAnti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer
Graphical Abstract
Synthesis of PLGA-PEG nanoparticles encapsulating docetaxel and conjugated to anti-CD24. Abbreviations: Cy7, Cy7 N-hydroxysuccinimide; MAL, maleimide; PLGA-PEG, poly(lactide-co-glycolide)-polyethylene glycol; PVA, polyvinyl alcohol.
Section snippets
Methods
Polyvinyl alcohol (PVA), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide-hydrochloride (EDC), dimethylsulfoxide (DMSO), docetaxel, Traut's reagent, and cellulose dialysis tubing were purchased from Sigma Aldrich Co. (St. Louis, MO, USA). Poly(lactide-co-glycolide)-polyethylene glycol (PLGA-PEG) and maleimide-PLGA-PEG were purchased from Akina Inc. (West Lafayette, IN, USA). Human anti-CD24 was procured from Abcam (Cambridge, MA, USA). Ethylenediamine dihydrochloride was purchased from Pierce
Characterization of PLGA-PEG nanoparticles
It was observed that void PLGA-PEG NPs and PLGA-PEG NPs encapsulating docetaxel with or without anti-CD24 conjugation were around 200 nm in diameter (Figure 2). The size and morphology were further confirmed by TEM (Figure 2, D); NPs were more or less spherically shaped and had the same size as found by DLS. The entrapment efficiency of the docetaxel in these NPs ranged from 70% to 75%, and loading efficiency was around 10% w/w in the nanoformulations of PLGA-PEG NPs encapsulating docetaxel
Discussion
The present study focused on PLGA-PEG NPs because of their ability to encapsulate active ingredients such as lipophilic drugs. Also, due to the presence of PEG, the NPs can evade the body's defense system and can stay in blood circulation for a longer time (by minimizing opsonization).24, 25 We selected higher molecular weights of PEG for the maleimide-PLGA-PEG than those in PEG-PLGA. This allowed maleimide functional groups to be available for conjugating the thiolated anti-CD24. The initial
References (36)
- et al.
CD24 is a marker for human breast carcinoma
Cancer Lett
(1999) - et al.
Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors
Gynecol Oncol
(2005) - et al.
Novel nanoparticles for the delivery of recombinant hepatitis B vaccine
Nanomedicine
(2008) - et al.
Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone
Eur J Pharm Biopharm
(2005) - et al.
PLGA nanoparticles prepared by nanoprecipitation: rug loading and release studies of a water soluble drug
J Control Release
(1999) - et al.
Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs
Biomaterials
(2005) - et al.
Murine models to evaluate novel and conventional therapeutic strategies for cancer
Am J Pathol
(2007) - et al.
PLA/PLGA nanoparticles for sustained release of docetaxel
Int J Pharm
(2006) Cancer facts and figures 2015
Prevalence and trends of selected urologic conditions for VA healthcare users
BMC Urol
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles
Proc Natl Acad Sci U S A
Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate
J Drug Target
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
N Engl J Med
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study
J Clin Oncol
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and leukemia group B
J Clin Oncol
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
N Engl J Med
Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation
Cancer Res
Cited by (43)
PLGA nanomedical consignation: A novel approach for the management of prostate cancer
2024, International Journal of PharmaceuticsNanotherapeutics for prostate cancer treatment: A comprehensive review
2024, BiomaterialsCurrent progress of nanomedicine for prostate cancer diagnosis and treatment
2022, Biomedicine and PharmacotherapyScreening strategies for surface modification of lipid-polymer hybrid nanoparticles
2022, International Journal of PharmaceuticsCitation Excerpt :Furthermore, this sligthly lower AE% reported for microfluidic-based formulations in comparison with that obtained for single-step nanoprecipitation-based nanocarriers might be associated with the reduced amount of DSPE-PEG2000-MAL present in this nanosystems. With the aim of developing tumour-targeted nanocarriers, the lipid-polymer hybrid nanoparticles obtained through the two formulation procedures under study were also functionalized with anti-CD24, an antibody against the membrane glycoprotein CD24, which is over-expressed in an important number of cancers (Bharali et al., 2017). For this purpose, nanoparticles were modified to exhibit NHS groups at the nanoparticle surface, by partially replacing DSPE-mPEG2000 by DSPE-PEG2000-NHS during the formulation process (maintaining a 75:25 DSPE-mPEG2000: DSPE-PEG2000 NHS proportion).
Targeted nanomedicine modalities for prostate cancer treatment
2021, Drug Resistance UpdatesLigand decorated biodegradable nanomedicine in the treatment of cancer
2021, Pharmacological ResearchCitation Excerpt :A reduction of prostate tumor weight and higher suppression of prostate tumor viability was also evident. On the contrary, DOCT delivered through PLGA-PEG nanoparticles alone showed increased drug concentration in the vital organs owing to their nonspecific targeting [36]. Sarisozen et al. [37] evaluated the synergistic effect of both curcumin (CUR) and DOX by encapsulating into pNP-PEG-PE micelles decorated with a single chain fragment variable (scFv) antibody against GLUT-1 into glioblastoma/glioblastoma multiforme (GBM) cells.
Conflicts of Interest: The authors report no conflicts of interest.
- 1
Equal contributors.
- 2
Present address: Pain and Spine Consultants, 1805 Williamson Court, Brentwood, TN, 37027, USA.